Q-Line Biotech Ltd.
SMENSE₹326–343
₹ 153 Cr
800 Shares
₹ 2,60,800
₹10
Financial Summary
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| 34,173.57 | 31,314.37 | |
| 570.34 | 1,207.61 | |
| 34,743.91 | 32,521.98 | |
| 24,363.9 | 25,150.37 | |
| 7,254.97 | 3,473.79 | |
| 5,572.17 | 1,568.23 |
Subscription Details
IPO Timeline
IPO Offer Start
21 May 2026
IPO Offer Ends
25 May 2026
29 May 2026
Use of Proceeds
| # | Purpose | Amount (₹ Million) |
|---|---|---|
| 1 | To meet Working Capital requirements | 935 |
| 2 | Repayment of certain borrowing availed by our Company, in part or full | 900 |
| 3 | General Corporate Purpose | 50.972 |
Promoters
Book Running Lead Managers
Promoter Shareholding
Pre-IPO
96.77%
Promoter stake
Post-IPO
67.51%
Promoter stake
Offered to Public
44,72,000
shares
Post Share Capital
1,57,50,000
shares
About the Company
We are engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. Our company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges. The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of Q-Line in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).
Use of Proceeds
1) To meet Working Capital requirements2) Repayment of certain borrowing availed by our Company, in part or full3) General Corporate Purpose.
Q-Line Biotech Ltd. Latest News
IPO FAQs
The Q-Line Biotech Ltd. IPO has a total of ₹153 crore, calculated at the upper end of the .
The Q-Line Biotech Ltd. IPO is priced at ₹326–343 per share. bids must fall within this , against a of ₹10 per share.
The for the Q-Line Biotech Ltd. IPO is 800 shares, which is also the minimum order quantity — you have to apply for at least 800 shares, and in multiples of 800 beyond that.
The minimum investment in the Q-Line Biotech Ltd. IPO is about ₹2,60,800 — one lot of 800 shares, calculated at the lower end of the .
Bidding at the cut-off or upper price raises the amount blocked in your account.
The Q-Line Biotech Ltd. opens on 21 May 2026 and closes on 25 May 2026.
Applications have to be in before 5:00 PM IST on the closing day, and your UPI mandate needs to be approved by then as well.
Q-Line Biotech Ltd. shares were listed on 29 May 2026 on NSE.
Purva Shareregistry (India) Pvt Ltd is the for the Q-Line Biotech Ltd. IPO.
The registrar processes the , refunds and the credit of shares to your demat account, so allotment-status queries go to them — email busicomp@vsnl.com.
Q-Line Biotech Ltd. IPO shares are listed on NSE.
Each Q-Line Biotech Ltd. share has a of ₹10.
Face value is the nominal value recorded in the company's books and is separate from the issue price you pay.
held 96.77% of Q-Line Biotech Ltd. before the IPO, which falls to 67.51% after the issue.
44,72,000 shares of Q-Line Biotech Ltd. are being offered to the public in this issue.
1) To meet Working Capital requirements2) Repayment of certain borrowing availed by our Company, in part or full3) General Corporate Purpose.
Hem Securities Ltd. and Share India Capital Services Pvt Ltd. are the for the Q-Line Biotech Ltd. IPO.
Pre-apply means placing your Q-Line Biotech Ltd. application before the subscription window actually opens. The bid is held and forwarded to the exchange on the opening day, so you don't have to submit it in the rush of the first morning.
Applying early doesn't improve your chances — when an issue is oversubscribed, the for investors is decided by a lottery, not by who applied first. Your money is only blocked once the application reaches the exchange.
You can apply in the Q-Line Biotech Ltd. IPO online using either UPI or ASBA as the payment method. ASBA applications are made through the net banking of a bank account that supports IPO applications — the bank blocks the amount in your account instead of debiting it. UPI applications are offered by brokers that don't provide banking services: you enter your UPI ID and then approve the mandate request in your UPI app.
Either route needs a demat account. You bid for at least one lot, at a price within the or at the cut-off price, and the money stays blocked in your bank account until the is finalised.
Your broker or bank confirms the bid once it has been submitted to the exchange, usually within a few minutes during the bidding window. A UPI application only goes live after you approve the mandate request — ignore it and the bid lapses, even though it looks placed.
You can check the Q-Line Biotech Ltd. bid independently on the NSE or BSE IPO bid-verification page a day after applying. An ASBA application also shows up as a blocked amount in your bank statement.